Delighted to share our new paper on rob PC-RPLND
🏥11 centers > 173 pts
🤖4% conversion rate: higher after salvage chemo and mass>5cm
🩸EBL 100, LOS 2d
➡️median FU 22mo: 8 recur (3 in-field)
↗️4yr RFS 93%
@Hoomandjaladat@EurUrolFocus@USC_Urology
🔗https://t.co/Z32MhsdADv
Amazing. IFN-alpha gene therapy is effective and FDA approved in bladder cancer. Thanks @ChapinMD for spreading the news. Product of decades of research led by Colin Dinney. https://t.co/m9wx5hDJWN
The @MDAndersonNews@UroOnc fellowship is ramping up for another year of applicant interviews
Watch for an open house in November
Contact me to set up an introduction at the @UroOnc meeting in December or @ASCO in Feb
Interview dates TBD (March/April 2022)
#oncsurgery
Talking about #BladderCancer for #UrologyWeek this year... Have we mentioned we have a special collection on the topic?
Guest Edited by @APMitra, the collection is an evidence based look into the management of bladder cancer.
Check it out! 📑
https://t.co/5sUBQQFZTA
#FOAMed
@UroDocAsh Per data by @AmerUrological 2022 match, #Urology ratio is 1.52, placing it in the highest quartile among specialities.
https://t.co/O8PBUkilbB
We're proud to welcome @DrDonnaHansel to MD Anderson as our next Division Head of Pathology and Laboratory Medicine.
Learn about this distinguished pathologist, researcher and leader, and the vital role she'll play in advancing our mission to #EndCancer: https://t.co/dx5kzO42bf
There's still time! ⌚
You can still submit to our open Special Collection, called
Management of Bladder Cancer: What is the evidence?
https://t.co/9FbRoslzpK
Guest Editor: Anirban P. Mitra @APMitra
Submission deadline: 31 August 2022
#callforpapers#urology#MedTwitter